Recent intervention studies suggesting a role for certain monoclonal antibody derived therapies such as donanemab may provide a stronger rationale for the identification and treatment of individuals found to be at high risk of dementia though high risk APOE genotypes or a very high HDL level.24 Here, APOE is linked to dementia.